Antisense Oligonucleotides for Targeted PKK Expression Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies are inadequate in effectively reducing plasma prekallikrein (PKK) expression, which contributes to inflammatory and thromboembolic conditions, and there is a need for targeted modulation of PKK mRNA and protein levels to treat associated diseases.
Innovation Solution
The use of antisense compounds, particularly antisense oligonucleotides, to specifically target and reduce PKK mRNA and protein expression in cells and tissues, including human tissues, through hybridization and modulation of gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to reduce PKK expression, then treatment of inflammatory and thromboembolic conditions is attempted, but the effectiveness in reducing PKK mRNA and protein levels is inadequate
Solution Approach 1:
The patent employs antisense oligonucleotides as intermediary molecules that specifically bind to PKK mRNA through complementary base pairing. These oligonucleotides act as mediators between the therapeutic goal (PKK expression reduction) and the molecular target (PKK mRNA), enabling precise and effective downregulation of PKK protein levels without affecting other coagulation factors
Solution Approach 2:
The invention utilizes chemical modifications of the oligonucleotide backbone (such as phosphorothioate modifications) and nucleotide composition adjustments to optimize the therapeutic parameters. By changing the chemical parameters of the antisense compound (stability, affinity, cellular uptake), the effectiveness of PKK expression reduction is significantly improved while maintaining specificity
2Manufacturing precision
If antisense compounds are used to target PKK mRNA, then specific reduction of PKK protein levels is achieved, but the complexity of the molecular therapy approach increases
Solution Approach 1:
The PKK mRNA target sequence is divided into multiple potential binding sites, allowing selection of optimal 15-30 nucleotide sequences that provide high specificity. The antisense compound itself is segmented into a defined length (15-30 nucleotides) that balances specificity with cellular delivery efficiency, avoiding overly long sequences that would increase complexity without adding benefit
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces PKK mRNA and protein levels in a time- and dose-dependent manner, providing therapeutic benefits in treating and preventing inflammatory and thromboembolic diseases such as hereditary angioedema and thrombosis.
Implementation Method 1
antisense compounds, particularly antisense oligonucleotides, to specifically target and reduce PKK mRNA and protein expression in cells and tissues, including human tissues, through hybridization and modulation of gene expression
Data Source
AI summary
Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.